U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07272057) titled 'SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes' on Nov. 18.
Brief Summary: The goal of this clinical trial
The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:
* Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
* Does it cause more or fewer cardiovascular toxicity?
* What side effects do participants experience? Researchers will com...